BTAI vs RF · rev $388.0K vs rev $1.75B
BioXcel Therapeutics Inc (BTAI) versus RF (RF) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
RF (RF) common stock.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
Latest reported RF revenue for 2026-06-30 was $1.75B. Net income was $570.0M. Revenue was up 2.7% from 2026-03-31 to 2026-06-30. RF currently screens at market cap $0.
BTAI currently screens at market cap $36.1M. RF currently screens at market cap $0.
Not investment advice. Open the BTAI and RF stock pages for the full models.
Not investment advice.